Patents Assigned to Upstream Bio, Inc.
  • Pharmaceutical composition comprising anti-human TSLP receptor antibody
    Patent number: 12447210
    Abstract: Provided is a stable pharmaceutical composition, comprising an anti-human TSLP receptor antibody, capable of inhibiting the generation of chemically modified substances, such as deamidated forms and oxidized forms, or degradants or multimers. The pharmaceutical composition comprises an anti-human TSLP receptor antibody, a pharmaceutically acceptable buffer, arginine or a pharmaceutically acceptable salt thereof, and a surfactant.
    Type: Grant
    Filed: June 8, 2023
    Date of Patent: October 21, 2025
    Assignee: Upstream Bio, Inc.
    Inventors: Megumi Ikeda, Akinori Chikushi
  • Pharmaceutical compositions comprising anti-human TSLP receptor antibodies and methods of using the same
    Patent number: 12150991
    Abstract: Pharmaceutical compositions of anti-TSLP-R antibodies, and uses thereof, are provided herein. The pharmaceutical compositions can comprise for example, an anti-TSLP-R antibody, or antigen-binding fragment thereof, a pharmaceutically acceptable buffer, an excipient, and a surfactant, or other compositions as provided for herein.
    Type: Grant
    Filed: November 7, 2023
    Date of Patent: November 26, 2024
    Assignee: UPSTREAM BIO, INC.
    Inventors: Parika Petaipimol, Robert Patrick Gearing, Bingquan Wang, Geng Li, Jeremy Guo
  • PHARMACEUTICAL COMPOSITION COMPRISING ANTI-HUMAN TSLP RECEPTOR ANTIBODY
    Publication number: 20230398213
    Abstract: Provided is a stable pharmaceutical composition, comprising an anti-human TSLP receptor antibody, capable of inhibiting the generation of chemically modified substances, such as deamidated forms and oxidized forms, or degradants or multimers. The pharmaceutical composition comprises an anti-human TSLP receptor antibody, a pharmaceutically acceptable buffer, arginine or a pharmaceutically acceptable salt thereof, and a surfactant.
    Type: Application
    Filed: June 8, 2023
    Publication date: December 14, 2023
    Applicant: UPSTREAM BIO, INC.
    Inventors: Megumi Ikeda, Akinori Chikushi
  • Pharmaceutical composition comprising anti-human TSLP receptor antibody
    Patent number: 11712472
    Abstract: Provided is a stable pharmaceutical composition, comprising an anti-human TSLP receptor antibody, capable of inhibiting the generation of chemically modified substances, such as deamidated forms and oxidized forms, or degradants or multimers. The pharmaceutical composition comprises an anti-human TSLP receptor antibody, a pharmaceutically acceptable buffer, arginine or a pharmaceutically acceptable salt thereof, and a surfactant.
    Type: Grant
    Filed: February 10, 2021
    Date of Patent: August 1, 2023
    Assignee: Upstream Bio, Inc.
    Inventors: Megumi Ikeda, Akinori Chikushi